Back to mobile site

Canaccord Genuity Reiterates a 'Buy' on Gen-Probe (GPRO); Good Q4; Solid Growth Prospects

February 14, 2012 9:03 AM EST
Get Alerts GPRO Hot Sheet
Price: $0.60 -4.76%

Rating Summary:
    4 Buy, 11 Hold, 6 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Gen-Probe (NASDAQ: GPRO) price target raised to $78.00.

Analyst, Jeffrey Frelick, said, "We reiterate our rating on GPRO following good Q4 results, solid 2012 guidance, growth prospects for the recently launched Trich and HPV assays, and the upcoming Panther launch in Q2/12."

"GPRO is increasing line, its R&D spending in 2012 for two major product developments: viral load assays and adding real-time PCR to Panther. As a result, we lower our 2012E EPS to $2.60 from $2.75 (vs. $2.50-2.68 guidance). Rolling out 2013 estimates. We are establishing our 2013 revenue and EPS estimates of $732M/$3.10."

For an analyst ratings summary and ratings history on Gen-Probe click here. For more ratings news on Gen-Probe click here.

Shares of Gen-Probe closed at $67.61 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change